Logan Lutton is a journalist at various esteemed publications including Patient Care and Medical Economics. He focuses on themes related to medicine and healthcare, with particular attention to dermatology, public health, and healthcare technology. Logan's work has been featured in notable outlets such as Physicians Practice, AJMC - The American Journal of Managed Care, and Drug Topics.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Logan Lutton's articles predominantly focus on healthcare and pharmaceuticals, with an emphasis on government announcements and data-driven insights. His work also delves into mental health, digital health, and medical updates.
Given the substantial coverage of government announcements and cited data in his articles, Logan might be interested in pitches featuring expert analysis or commentary related to recent policy changes or new research findings within the healthcare industry. Additionally, he may respond well to pitches that offer innovative perspectives on digital health technology or insights into emerging trends in mental health treatment.
As a journalist focused nationally within the United States, professionals with expertise in U.S. healthcare policies & regulations or those involved in cutting-edge research at American institutions are likely to resonate more effectively with him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Logan Lutton
In this discussion, Jorge Nieva, M.D., professor of clinical medicine at the University of Southern California Norris Comprehensive Cancer Center, explores how pesticide exposure from otherwise “healthy” diets may help explain the rise of early-onset lung cancer in non-smokers.
By: Logan Lutton
Lung cancer has shifted from a rare, smoking-driven disease to one increasingly seen in young non-smokers, especially women, with possible links to pesticide exposure from otherwise “healthy” diets.
By: Logan Lutton
Financial sustainability and innovation are interdependent, as clinician-led contracting strategies that improve outcomes generate savings that fund further innovation.
Built from the experiences of patients, advocates and clinicians, a new MASH patient journey map offers a roadmap for navigating diagnosis and highlights the need for greater public understanding of the disease.
By: Logan Lutton
In this interview, Marc Elia argues that monoclonal antibodies like VYD2311 offer a fundamentally different approach to COVID-19 prevention than vaccines, delivering protective antibodies directly rather than triggering an immune response, which he says could improve tolerability.
By: Logan Lutton
A phase 3b trial found that Otsuka's centanafadine significantly improved both ADHD symptoms and anxiety symptoms in adults with ADHD and comorbid anxiety, with effects emerging as early as week 1 and holding through 8 weeks, as the drug awaits an FDA decision expected July 24, 2026.
By: Logan Lutton
Marc Elia of Invyvid explains the difference between vaccines and monoclonal antibodies.
By: Logan Lutton
A new study in JAMA Network Open projects that the number of Medicare beneficiaries 65 and older living with HIV will grow from approximately 122,000 to 194,000 by 2035, driving cumulative Medicare costs of $187.2 billion, with antiretroviral therapy alone accounting for 63% of that spending.
By: Logan Lutton
A former radiation oncologist turned chief medical officer, Rex Hoffman, M.D., MBA, has spent the past several years expanding his leadership footprint across Providence Holy Cross Medical Center's health system while authoring multiple books aimed at helping physicians navigate the transition into executive roles.
By: Logan Lutton
In this conversation, Johns Hopkins researchers describe a newly identified population of brainstem neurons that are crucial for selective attention in mice and may offer fresh insight into ADHD in humans.
